NetwoRx Bio predicts patient response to cancer immunotherapy using high-resolution tumor-immune interaction analytics, enabling precision medicine, smarter clinical trial design, and optimal drug-indication matching. Unlike others, we map all known ligand-receptor pairs across 30+ cell types to deliver mechanistic insights—not mere correlations. Our platform operates independently of pharma data, providing rapid, biology-driven predictions that reduce trial risk and unlock value across the $50B immunotherapy (ICI) market.